Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

250 Articles

Jon C. Ogg | Jul 31, 2012 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades (BSFT, PRSS, CBI, CMCSA, DNDN, DOW, FB, FGP, GSK, LVS, PMCS, RYAAY, STO, TSRA, TWC, VRTX)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday…

Jon C. Ogg | Jul 16, 2012 at 10:43 AM EDT

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to…

Jon C. Ogg | Jul 10, 2012 at 7:35 AM EDT

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks…

Jon C. Ogg | Jul 2, 2012 at 2:42 PM EDT

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value…

Jon C. Ogg | May 29, 2012 at 8:04 AM EDT

Vertex ‘Correction’ to Cystic Fibrosis Destroys Billions in Value (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was very close to 52-week highs of late, but that will not be the case…

Jon C. Ogg | May 14, 2012 at 8:33 AM EDT

Top Analyst Upgrades & Downgrades

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Monday.…

Jon C. Ogg | May 10, 2012 at 8:25 AM EDT

Top Analyst Upgrades & Downgrades (ARMH, BIG, CHKM, CSCO, CPWM, DLB, HGSI, JDSU, LINE, MMM, NOV, ORCL, RGP, TPX, TLLP, TEVA, VRTX)

These are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Thursday. ARM…

Jon C. Ogg | May 8, 2012 at 1:15 PM EDT

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)

When we issued our earnings previews for the week ahead, it looked as though Dendreon Corporation (NASDAQ: DNDN) had a…

Jon C. Ogg | May 8, 2012 at 8:11 AM EDT

Top Analyst Upgrades & Downgrades (ACM, ALNY, BIIB, BP, COF, SNP, CTSH, EA, EPB, ERJ, F, LPX, MFC, MM, RAX, SYNC, VRTX, WYNN)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday.…

Paul Ausick | May 7, 2012 at 4:08 PM EDT

24/7 Wall St. Closing Bell (FSLR, PEP, PG, ILMN, CCL, ANV, AWR, BBEP, CDE, DISH, LPX, TSN, HFC, CHTR, DMD, HL, OMX, THC, WEN, DIS, VRTX, CTSH, BSFT)

The major US stock indexes opened lower this morning following a weekend of elections in Europe. A new Socialist party…

Jon C. Ogg | May 7, 2012 at 8:54 AM EDT

Vertex Sees Billions In Value on Cystic Fibrosis Results (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is trading up so much higher that you might think the company is being acquired. …

Jon C. Ogg | Apr 17, 2012 at 8:27 AM EDT

Top Analyst Upgrades & Downgrades (ACHN, AAPL, BSX, CLS, C, CTRN, FSLR, HAIN, IDIX, INFY, NCT, SAP, TNK, TIF, VLO, VRTX)

Jon OggThese are some of today’s top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday.…

Jon C. Ogg | Apr 4, 2012 at 1:28 PM EDT

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment…

Jon C. Ogg | Feb 17, 2012 at 10:33 AM EST

Gilead Defended By Analyst As Competitors Gain Momentum (GILD, BMY, VRTX, ACHN)

Gilead Sciences, Inc. (NASDAQ: GILD) has recovered from its pre-market lows on the devastating news that its Hepatitis C drug…

Jon C. Ogg | Feb 2, 2012 at 4:29 PM EST

Vertex Outlines 2012 Sales Expectations (VRTX)

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is trading lower after earnings, but this may be due more to a give back from…

1 … 12 13 14 15 16 17

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

Top Analyst Upgrades and Downgrades (BSFT, PRSS, CBI, CMCSA, DNDN, DOW, FB, FGP, GSK, LVS, PMCS, RYAAY, STO, TSRA, TWC, VRTX)

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

Vertex ‘Correction’ to Cystic Fibrosis Destroys Billions in Value (VRTX)

Top Analyst Upgrades & Downgrades

Top Analyst Upgrades & Downgrades (ARMH, BIG, CHKM, CSCO, CPWM, DLB, HGSI, JDSU, LINE, MMM, NOV, ORCL, RGP, TPX, TLLP, TEVA, VRTX)

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)

Top Analyst Upgrades & Downgrades (ACM, ALNY, BIIB, BP, COF, SNP, CTSH, EA, EPB, ERJ, F, LPX, MFC, MM, RAX, SYNC, VRTX, WYNN)

24/7 Wall St. Closing Bell (FSLR, PEP, PG, ILMN, CCL, ANV, AWR, BBEP, CDE, DISH, LPX, TSN, HFC, CHTR, DMD, HL, OMX, THC, WEN, DIS, VRTX, CTSH, BSFT)

Vertex Sees Billions In Value on Cystic Fibrosis Results (VRTX)

Top Analyst Upgrades & Downgrades (ACHN, AAPL, BSX, CLS, C, CTRN, FSLR, HAIN, IDIX, INFY, NCT, SAP, TNK, TIF, VLO, VRTX)

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

Gilead Defended By Analyst As Competitors Gain Momentum (GILD, BMY, VRTX, ACHN)

Vertex Outlines 2012 Sales Expectations (VRTX)

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

Top Analyst Upgrades and Downgrades (BSFT, PRSS, CBI, CMCSA, DNDN, DOW, FB, FGP, GSK, LVS, PMCS, RYAAY, STO, TSRA, TWC, VRTX)

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

Vertex ‘Correction’ to Cystic Fibrosis Destroys Billions in Value (VRTX)

Top Analyst Upgrades & Downgrades

Top Analyst Upgrades & Downgrades (ARMH, BIG, CHKM, CSCO, CPWM, DLB, HGSI, JDSU, LINE, MMM, NOV, ORCL, RGP, TPX, TLLP, TEVA, VRTX)

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)

Top Analyst Upgrades & Downgrades (ACM, ALNY, BIIB, BP, COF, SNP, CTSH, EA, EPB, ERJ, F, LPX, MFC, MM, RAX, SYNC, VRTX, WYNN)

24/7 Wall St. Closing Bell (FSLR, PEP, PG, ILMN, CCL, ANV, AWR, BBEP, CDE, DISH, LPX, TSN, HFC, CHTR, DMD, HL, OMX, THC, WEN, DIS, VRTX, CTSH, BSFT)

Vertex Sees Billions In Value on Cystic Fibrosis Results (VRTX)

Top Analyst Upgrades & Downgrades (ACHN, AAPL, BSX, CLS, C, CTRN, FSLR, HAIN, IDIX, INFY, NCT, SAP, TNK, TIF, VLO, VRTX)

Abbott’s Hep-C Pressures All Hep-C Rivals (ABT, RIGL, GILD, VRTX, IDIX)

Gilead Defended By Analyst As Competitors Gain Momentum (GILD, BMY, VRTX, ACHN)

Vertex Outlines 2012 Sales Expectations (VRTX)

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do